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Abstract
Melatonin is an indolamine produced by the pineal gland and it can exert a potent antioxidant effect. Its free
radical scavenger properties have been used to advantage in different organ transplants in animal experiments.
Several concentrations and administration pathways have been tested and melatonin has shown encouraging
beneficial results in many transplants of organs such as the liver, lungs, heart, pancreas, and kidneys. The objective
of the present study was to review the scientific literature regarding the use of melatonin in ovary transplantation.
A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
statement was carried out using the Cochrane and Pubmed databases and employing the terms ‘melatonin’ AND
‘ovary’ AND ‘transplantation.’ After analysis, 5 articles were extracted addressing melatonin use in ovary transplants
and involving 503 animals. Melatonin enhanced various graft aspects like morphology, apoptosis, immunological
reaction, revascularization, oxidative stress, and survival rate. Melatonin’s antioxidative and antiapoptotic properties
seemingly produce positive effects on ovarian graft activity. Despite the promising results, further studies in humans
need to be conducted to consolidate its use, as ovary transplantation for fertility preservation is gradually being
moved from the experimental stage to a clinical setting.
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Background
Melatonin is an indolamine produced mainly by the pin-
eal gland [1, 2] and it has a potent freeradical scavenger
activity with subsequent antioxidant and antiapoptotic
functions [1, 3, 4]. Unlike vitamin C, which is hydro-
philic, and vitamin E, which is lipophilic, the melatonin
molecule carries both hydrophilic and lipophilic affinities
and therefore diffuses broadly in diverse subcellular
compartments like the membranes, cytoplasm, nucleus,
and mitochondria [1, 4]. It has thus the ability to pro-
duce its antioxidative action rapidly and effectively as
soon as the oxidative agents are produced [5]. There are
reports about melatonin action on the rat ovary specific
receptors MT1 and MT2 [6].
There are also studies indicating that one of the main
challenges in achieving a successful transplant, is the re-
duction in graft follicular loss and damage. This is
attainable through mitigation of the free radicals pro-
duced by the procedure [7] and primarily originating
from ischemia-reperfusion distress [5]. Melatonin’s im-
munological and antiapoptotic properties are seen as po-
tentially implicated in the enhancement of transplantation
success [5], a welcome improvement even in heterologous
and autologous grafting. There are other studies demon-
strating the benefits of melatonin in experimental trans-
plants of organ, like the liver [8], lungs [9], heart [10],
pancreas [11, 12] and kidneys [13]. Enhancement of the
graft function, immunological compliance, and antiapop-
totic and antioxidative status are examples of the positive
outcome.
As there is evidence that melatonin’s properties may
experimentally improve the transplants of a variety of
organs along different pathways, the aim of this review
was to gather published studies of the indolamine’s use
in ovary transplantation.
Methods
In this systematic review, the PubMed and Cochrane
databases were searched for reports published in any
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language between October 1, 2003 – date of the first
ever published related paper [14] – and October 31,
2015, with the search terms: ‘melatonin’ AND ‘ovary’
AND ‘transplantation.’
Data were extracted from the selected articles. Qual-
ity assessment was performed independently by two
reviewers (M.E.S. and N.M.B.). When there was any
disagreement, a third reviewer (L.L.D.) was consulted.
The analysis followed the PRISMA statement for sys-
tematic reviews [15].
Six studies were identified and after detailed analysis
of the content, one of them [16] was excluded for issue
discrepancy (Fig. 1).
Results
All of the selected studies were published in the 12 years
previous to this review. A total of 503 rodents (mice and
rats) were studied. There are no reports of animal loss.
Notwithstanding a study which used 5 human xeno-
transplanted ovarian samples, all were studies which
experimentally analyzed the effects of melatonin on
animals.
Except in the pioneer study by Sapmaz [14], who
employed fresh ovaries, in all other researches, grafts
were frozen and thawed. Many different concentrations
(for the maintenance solution of the graft) and appli-
cation routes (oral and intraperitoneal) were studied.
Two studies adopted similar methodology and could
be paired [17, 18].
The biological effects of melatonin on graft were
enhancement of morphology; revascularization; and
improved survival rate with concomitant reduction in
apoptosis, immunological Th1/Th2 lymphocyte reaction,
and oxidative stress (a decrease in oxidative factors and
an increase in antioxidative agents). Results are summa-
rized in Table 1.
Conclusions
The potential effects of melatonin use in animal ovary
transplantation align with previously reported positive
findings of its application in many experimental trans-
plants of such organs as the liver [8], lungs [9], heart
[10], pancreas [11, 12] and kidneys [13].
In our review we found evidence of the effects of
melatonin on ovarian graft. Notwithstanding the admin-
istration routes (oral or intraperitoneal) and vehicles
(graft), the selected studies reported a promising per-
formance of the indolamine. This points to a wide solu-
bility which enables it to spread rapidly throughout a
variety of tissues. The effects comprised a wide range of
properties, including follicle morphology and dynamics,
apoptosis, graft survival range, immunologic activity and
antioxidative mechanisms. The potent antioxidative
properties of melatonin, along with its free radical
scavenger activity, decrease oxidative stress and thus
increase the survival rate. Melatonin not only acts dir-
ectly as an anti-free radical agent, but also activates
other enzymes, such as superoxide dismutase, gluta-
thione peroxidase, and catalase [20, 21], with the po-
tential to decrease oxidative damage. Even melatonin
metabolites have free radical scavenger properties,
thus triggering multiple synergistic antioxidative fac-
tors, a phenomenon referred to as the cascade effect
[20, 21]. The antiapoptotic effect was also remarkable
and is based on reduction of Bcl2 expression and
caspase-3 activity [22]. The enhancement of ovarian
graft function is also attributable to melatonin, given
that it is known to modulate steroidogenesis and
ovulatory function [23, 24]. The subsequent balance
between free radicals and antioxidative substances in
the ovarian follicle also improves oocyte and granulosa
cell function [1, 2, 21]. Additionally, the indol also
attenuated immunological reaction and improved
Fig. 1 Algorithm of selected studies
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Table 1 Effects of melatonin on ovary transplantation





Xenotransplanted thawed graft; donor: 5 cancer patients
aged 6–23 years; recipient: 79 immunodeficient nu/nu
Balb/c mice aged 10–12 weeks
Oral administration in feeding
water; 240 mg/L
Reduced number of apoptosis and atretic follicles
Hemadi,
2012 [19]
Balb/c mice Heterologous thawed graft; donor: mice aged 10 days; recipient: 180
mice aged 8–10 weeks; 900 transplants
Oral administration; 20–200 mg/
kg/day
Enhanced follicle quality, quantity, and graft size with low
dosage; diminished Th1/Th2 immunological reaction and
longer graft lifespan with high dosage
Hemadi,
2011 [18]
F1 hybrid mice Heterologous thawed graft; donor: mice aged 10 days; recipient: 60
mice aged 8–10 weeks
Graft: 100 μM PBF
Recipient: intraperitoneal for
2 days; 20 mg/kg/day
Enhanced corpora lutea, secondary and antral follicles
Hemadi,
2009 [17]
F1 hybrid mice Heterologous thawed graft; donor: 120 mice aged 10 days; recipient:
36 mice aged 8–10 weeks
Graft: 100 μM PBF
Recipient: intraperitoneal for
2 days; 20 mg/kg/day








Diminished ovarian and plasmatic malondialdehyde and














revascularization, two essential properties for a suc-
cessful graft allocation.
The present review has some limitations imposed by
the studies it covered. The heterogeneity of methods
made it difficult to compare results. The wide range of
apparently beneficial melatonin action on ovarian trans-
plantation is quite encouraging, but melatonin was stud-
ied only in animal models. Moreover, except for the
Sapmaz [14] study, the other studies employed heterol-
ogous or xenotransplantation, which differs from clinical
preservation of human fertility, for this method requires
autologous transplantation. Melatonin was administered
in the feeding water in two studies [3, 19]. Therefore,
different water intake by the animals might have resulted
in diverse plasmatic concentration of melatonin. Apart
from Hemadi [19], who dosed melatonin plasmatic
levels, the authors did not determine the in vivo avail-
ability of melatonin in blood or urine. Furthermore, no
study used control animals (not even pinealectomized
rodents or rodents submitted to continuous light) to iso-
late the effect of endogenous melatonin production.
Melatonin’s antioxidative and antiapoptotic properties
seem to produce positive effects on ovarian graft. Des-
pite the promising results, further studies are needed in
humans to consolidate its use, as ovary transplantation
for fertility preservation is gradually being moved from
the experimental stage to a clinical setting.
Abbreviation
PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses
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